Form 8-K - Current report:
SEC Accession No. 0001842952-24-000081
Filing Date
2024-09-17
Accepted
2024-09-17 16:22:23
Documents
15
Period of Report
2024-09-17
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntx-20240917.htm   iXBRL 8-K 39069
2 EX-3.1 exhibit31.htm EX-3.1 8431
3 EX-3.2 exhibit32.htm EX-3.2 30105
  Complete submission text file 0001842952-24-000081.txt   227733

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20240917.xsd EX-101.SCH 1937
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20240917_lab.xml EX-101.LAB 25275
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20240917_pre.xml EX-101.PRE 14678
17 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20240917_htm.xml XML 3101
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 241304712
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)